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Introduction
Somatic cell reprogramming is carried out by exogenous 
expression of four pluripotency-associated transcription 
factors, c-Myc, Oct-4, Klf4 and Sox2, known as 
‘Yamanaka’ factors. Th   e groundbreaking experiment that 
identiﬁ   ed the minimal requirement of these four 
transcription factors screened 24 essential embryonic 
stem cell (ESC)-expressing genes by retroviral intro-
duction into mouse embryonic ﬁ   broblasts [1]. Th  is 
pioneering study utilized the neomycin resistance gene 
knocked into the endogenous Fbx15 locus as a reporter 
of reprogramming. Upon isolation of ESC-like G418 
resistant colonies, detailed characterization demon  stra-
ted a transition of diﬀ  erentiated cells to pluripotency, 
although attempts to generate adult chimeric mice were 
unsuccessful. Th   is initial report stressed the importance 
of epigenetic remodeling during the acquisition of 
pluripotency and demonstrated that key endogenous 
pluripotency genes such as Nanog and Oct-4 acquired 
transcriptionally permissive chromatin structure at their 
promoters, characterized by DNA hypomethylation, 
histone H3K9 demethylation and acetylation of histone 
H3. However, it was immediately clear that inherent 
hetero  geneity exists among cells undergoing the repro-
gramming process and signiﬁ  cant  diﬀ  erences  between 
established induced pluripotent stem (iPS) cell and ESC 
transcriptomes were evident. Two subsequent studies 
utilized an improved selection protocol by selecting for 
the expression of Nanog or Oct-4 rather than Fbx15 [2-4]. 
Using the Nanog  selection strategy, Mikkelsen and 
colleagues [2] identiﬁ  ed two distinct reprogrammed iPS 
cell populations, with Nanog  selection at later repro-
gramming stages (that is, day 30 post-infection) enriching 
for more ESC-like, fully reprogrammed iPS cells.
Appropriate downstream applications of iPS cells for 
developing  in vitro disease models or therapeutic 
purposes are absolutely dependent on the fact that 
artiﬁ  cially derived iPS cells do indeed behave like ESCs 
under the same conditions. To this end, the ﬁ  nding that 
Nanog selected iPS cells are diﬀ   erent and of higher 
quality than the Fbx15 selected iPS cells underlined early 
on the importance of selecting the right reporting 
strategy to isolate and characterize the iPS cells of the 
highest quality. Indeed, genome-wide transcription 
analy  sis revealed wide-ranging changes in gene expres-
sion between the two selection processes [5]. Further-
more, markers of complete reprogramming are not 
exactly the same in the mouse and human systems; for 
instance, Nanog reactivation in human iPS cells does not 
speciﬁ   cally mark fully reprogrammed iPS cells, and 
alternative markers, such as DNMT3B [6] and perhaps 
hTERT expression levels [7], are better indicators of this 
developmental stage. On the other hand, retroviral 
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occurrence in completely reprogrammed mouse and 
human iPS cells [1,5,6,8,9]. Our lab has recently developed 
a lentiviral EOS reporter vector for the isolation and 
expansion of pluripotent stem cells, although EOS 
enriches for, but does not speciﬁ   cally mark, fully 
reprogrammed mouse iPS cells [10]. In the human iPS 
cell system, multiple markers of full re  programming may 
need to be utilized, including iPS cell colonies of desirable 
morphology, gene expression and cell surface marker 
expression, such as Tra-1-60 and SSEA4. However, since 
generating chimeras is not an option in the human iPS 
cell context, these surrogate markers together with 
teratoma formation are likely to remain the most 
stringent way to demonstrate full reprogramming.
Robustness of somatic cell reprogramming using 
‘Yamanaka’ factors is evident when considering the 
sources of somatic cells used in reprogramming experi-
ments, including liver and stomach [11], blood [12], 
pancreas [13] and the intestine [14]. Th   e requirement for 
the exogenous factors is variable depending on the 
starting cell type, with a recent paper reporting the 
derivation of iPS cells using only Oct-4 in neural stem 
cells [15]. Collectively, these ﬁ  ndings demonstrate that 
the epigenetic landscapes that characterize diﬀ  erent 
somatic cell types can be reorganized using a similar 
cocktail of transcription factors as the initiator of 
reprogramming, with Oct-4 playing a central and 
seemingly irreplaceable role in the reprogramming 
cascade. It remains to be determined whether somatic 
cells of diﬀ  erent tissues of origin have distinct epigenetic 
structures that are more permissive to the derivation of 
fully reprogrammed iPS cells. Alternatively, there may be 
elite subsets of cells that are more epigenetically 
predisposed to reprogramming that are yet to be 
discovered [16]. However, a recent study by Hanna and 
colleagues [17] demonstrated by single cell sorting of 
terminally diﬀ  erentiated secondary mouse B cells that 
every cell has the potential of giving rise to Nanog-green 
ﬂ  uorescent protein activated iPS cell populations, albeit 
at diﬀ  erent reprogramming rates, indicating that somatic 
cell reprogramming involves stochastic mechanisms.
Epigenetic restructuring during reprogramming
Although induced pluripotency is dependent on exoge-
nously introduced transcription factors, the epigenetic 
changes that take place during reprogramming are the 
driving force of a gradual transition to the pluripotent 
state. Th   e pioneering studies provided the evidence that, 
in the mouse system, transition to pluripotency is accom-
panied by global epigenetic changes. We view these 
changes as a seven headed dragon, with the heads 
representing: 1, epigenetic reactivation of endogenous pluri-
potency genes, such as Oct-4 and Nanog; 2, establishment 
of bivalent chromatin domains at developmental loci and 
altered histone H3K4 and H3K27 trimethylation levels at 
ESC ‘signature’ gene promoters [2] (bivalent mechanisms 
are reviewed in [18]);  3, hetero  chromatin DNA hypo-
methylation of satellite repeats [4]; 4, inactive-X chromo-
some reactivation in female iPS cells; 5, maintenance of 
DNA methylation marks of imprinted gene loci [5]; 6, 
retroviral transgene silencing upon pluripotency establish-
ment; and 7, the possibility that these molecular epigenetic 
modiﬁ   cations are accom  panied by three-dimensional 
reorganization of chromatin ﬁ  ber structures and nuclear 
subdomain localization (summarized in Figure 1). It is 
apparent that pluripotent ESCs and iPS cells share distinct 
epigenetic regulatory pathways, characterized both by the 
existence of bivalent chromatin domains and extensive 
DNA methylation marks at non-CpG dinucleotides [19].
Complete reprogramming is a rare event in a sea of 
intermediate cells
It is now well established that at least three classes of cells 
are derived during reprogramming, termed intermediate, 
partially (or pre-iPS) and fully reprogrammed iPS cells. 
However, only the latter two are capable of forming ESC-
like colonies that are commonly isolated during the 
clonal expansion of iPS cell lines. Th  e reprogramming 
process is a rare event, with initial studies reporting the 
reprogramming eﬃ   ciencies in mice of 0.1% of the starting 
cell numbers giving rise to visible colonies on the 
induction plates. Th  is number is even smaller when 
considering only colonies that are fully reprogrammed 
with all the epigenetic characteristics of an ESC-like 
state. Indeed, most of the cells that initiate the 
reprogramming process fail to contribute to the germline 
of adult chimeric mice [1,3,6,20]. Even though the 
establishment of partially reprogrammed iPS cells is 
undesirable for subsequent diﬀ   erentiation and disease 
modeling experiments, continued characterization of 
such cell lines will provide clues as to the various blocks 
to bona ﬁ  de reprogramming to occur [2].
When retroviral transgene delivery is used for the 
reprogramming process, continued dependence on the 
transgene expression is a hallmark characteristic of 
partially reprogrammed iPS cells. Th  is  persistent 
retroviral expression is rarely observed upon endogenous 
Sox2  [21] or Nanog [22,23] activation. Genome-wide 
transcriptional analysis of partially reprogrammed cell 
lines indicates that activation of ESC-speciﬁ  c genes by 
the Yamanaka factors requires cooperative interaction 
with additional pluripotency-associated genes not present 
in the partially reprogrammed cells, such as Nanog [24]. 
Th  is  diﬀ  erential binding of transcription factor complexes 
is not accounted for by the persistence of histone 
H3K27me3 chromatin marks of the ESC-speciﬁ  c target 
genes by the four reprogramming factors, implicating 
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to be the main driving force of the reprogramming 
process, its association in transcriptional activator or 
repressor complexes in combination with epigenetic 
modifying enzymes is worth considering. Recently, Oct-4 
was shown to be a member of the Nanog and Oct4-
associated deacetylase (NODE) repressor complex 
consisting of Nanog, histone deacetylase (HDAC)1/2 and 
Mta1/2 and members of repressor chromatin remodeling 
complexes NuRD and Sin3A [25]. Knockdown of the 
components of the NODE complex leads to upregulation 
of developmentally regulated target genes and ESC 
diﬀ  erentiation towards the endoderm lineage. Interest-
ingly, an independent study has demonstrated that a 
member of the NuRD complex, Mbd3 (methyl CpG-
binding domain protein 3), is involved in the repression 
of primitive endoderm and trophoblast-speciﬁ  c  genes 
Gata6 and Cdx2, respectively [26]. In addition, Oct-4 
interacts with SetDB1/Eset, a histone H3K9 methyl-
transferase, to restrict the expression of extra-embryonic 
lineage genes in the inner cell mass (ICM) of the 
developing blastocyst [27]. It would be interesting to 
determine whether transient overexpression of Eset and 
the NODE complex remodeling enzymes could increase 
the derivation of completely reprogrammed iPS cells 
during the late stages of the reprogramming process. 
Indeed, various chemical treatments speciﬁ  cally targeting 
silencing epigenetic regulators of transcription increase 
the eﬃ   ciency of induction to pluripotency.
Small molecule treatments increase reprogramming 
effi   ciencies
Somatic cell reprogramming is proposed to be a stochastic 
event [17], requiring precisely coordinated levels of 
trans  gene expression at the right time [8,21], and this 
ineﬃ     ciency is at least partly due to epigenetic blocks 
encountered on the road to pluripotency. Th  is  is 
convincingly demonstrated by the series of experiments 
in the mouse system using chemical inhibitors of 
chroma  tin remodeling enzymes, G9a (histone H3K9 
methyl  transferase) [28], HDACs [29], and DNA methyl-
transferases (DNMTs) [2,28], yielding higher reprogram-
ming eﬃ   ciencies in a variety of cell types (reviewed in 
[30,31]). However, it remains unresolved whether most 
chemical treatments only increase the eﬃ   ciency of early 
reprogramming events yielding a higher number of 
partially reprogrammed iPS cells. To date, two chemical 
treatments have been shown to induce the conversion of 
a stable partial iPS cell line to the fully reprogrammed iPS 
cell state. Th  ese conversions used 5AzaC (a DNMT 
inhibitor) treatment of B-cell derived iPS cells and the 
heterogeneous MCV8 iPS cell line [2] or treatment with a 
2i/leukemia inhibitory factor (LIF) inhibitor cocktail 
targeting mitogen-activated protein (MEK)/extracellular 
signal-regulated kinase (ERK) and glycogen synthase 
kinase-3 (GSK3) pathways [24,32]. However, only 2i/LIF 
treatment was shown to result in partial iPS cells 
converting to germline competent fully reprogrammed 
iPS cells. Since individual partially reprogrammed iPS 
cells are arrested at diﬀ   erent reprogramming stages, 
clonal lines respond diﬀ  erently to the reported chemical 
conversion approaches. In fact, Mikkelsen and colleagues 
[2] reported that an additional partially reprogrammed 
iPS cell line, MCV6, responded to the 5AzaC-mediated 
conversion to the pluripotent state only upon short 
hairpin RNA knockdown of four lineage-specifying 
transcription factors. In addition, Chd1, a euchromatin-
speciﬁ  c chromatin remodeling enzyme, has been shown 
to maintain the pluripotent ESC state and its absence 
impedes the somatic cell reprogramming process [33]. 
Overall, the data so far suggest that repressive epigenetic 
modiﬁ   ers result in various blockades to the 
reprogramming process. However, it is important to note 
that chemical inhibition of key epigenetic regulatory 
mechanisms within speciﬁ  c pluripotent cells may have 
Figure 1. Dynamic epigenetic changes characterize the 
gradual reprogramming process. Four stages of reprogramming 
are illustrated as diff  erentiated starting cell type (that is, murine 
embryonic fi  broblasts), intermediate, partially reprogrammed 
induced pluripotent stem (iPS) cells and fully reprogrammed iPS 
cells. Activation of pluripotency-associated loci results in iPS cells’ 
ability to stably self-renew and precisely control the embryonic stem 
cell (ESC)-like transcriptional profi  le. Proper histone methylation 
levels at the right genomic regions establishes bivalent chromatin 
domains not necessarily involved in the induction to pluripotency 
but required for proper diff  erentiation capacity of iPS cells. DNA 
methylation levels are reduced in female ESC and iPS cell lines at 
heterochromatic satellite repeat elements. The functional signifi  cance 
of DNA hypomethylation is currently not understood but could be 
a refl  ection of the reactivated inactive-X chromosome. On the other 
hand, DNA methylation marks of imprinted genes remain protected 
from demethylation and are comparable to the levels in the starting 
cell type. Finally, it is not known whether extensive epigenetic 
changes accompanying the reprogramming process result in 
physical structural changes to the chromatin fi  bers themselves.
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methylation prematurely in the reprogramming process 
results in apoptosis of the intermediate cell types [34] 
and may induce DNA damage response pathways [35], 
while inhibition of HDACs results in diﬀ  erentiation of 
ESCs [36]. Th   us, precise timing of the chemical treatments 
during the reprogramming process is required to achieve 
optimal conditions for the induction of pluripotency.
Currently, multiple epigenetic hallmark characteristics 
have been assigned to the fully reprogrammed iPS cell 
state. Since a wide range of global epigenetic 
modiﬁ  cations are taking place during the reprogramming 
process, the question of changes to the physical 
chromatin architecture becomes an interesting feature to 
explore. It has been known for a long time that ESC 
genomes are characterized by a more ‘open’ chromatin 
state but its role in pluripotency is diﬃ   cult to ascertain. A 
wide range of epigenetic reconﬁ  guration is carried out 
during the formation of the ICM, including random X-
inactivation and resetting of loci-speciﬁ  c  histone 
methylation levels. Th   erefore, genomic ‘euchromatiniza-
tion’ may be a consequence of such epigenetic repro-
gram  ming events. However, an interesting possibility to 
consider is that establishment of more open, plastic 
chromosome territories within the nucleus is required 
for the cells of the ICM to respond to diﬀ  erentiation cues 
properly. Such a physical state would allow for quick 
reconﬁ  guration of the chromatin state throughout this 
early embryonic development. Th  is is supported by the 
fact that nucleosomal proteins are not static chromatin 
units in pluripotent stem cells, but rather exist in a 
hyperdynamic state where rapid exchange occurs 
throughout the cell cycle [37]. Th   e reprogramming stage 
at which such conformational changes to the chromatin 
state are established remains to be explored in future iPS 
cell studies.
Applications of induced pluripotent stem cells
Th  e process of artiﬁ   cial somatic cell reprogramming 
using deﬁ  ned factors will undoubtedly have a tremendous 
impact on the way we study human disease and will likely 
have applications in the ﬁ  eld of regenerative medicine. 
Currently, eﬀ  orts are being made to diﬀ  erentiate iPS cells 
and ESCs down diﬀ  erent lineages into somatic cell types 
by recapitulating the in vivo diﬀ  erentiation cues in vitro 
[38,39] (and reviewed in [40]). Signaling molecules, such 
as activin A and bone morphogenetic protein, used in 
diﬀ  erentiation studies are also expressed in the develop-
ing embryo. Th   ese strategies have provided the proof of 
concept of the potential use of ESCs and iPS cells in 
regenerative medicine and disease modeling in humans. 
In vitro modeling of human disease for small molecule 
screening will likely become the ﬁ   rst use of iPS cell 
technology for ‘real-life’ applications. In fact, iPS cell 
lines have been established from patients with multiple 
diseases, such as amyotrophic lateral sclerosis [41], 
familial dysautonomia [42], fanconi anemia [43], rett 
syndrome [10], spinal muscular atrophy [44] and a 
spectrum of other diseases [45]. Several of these studies 
demonstrated directed iPS cell diﬀ  erentiation to aﬀ  ected 
cell types with Ebert and colleagues [44] and Lee and 
colleagues [42] reporting the ﬁ  rst successful phenotype 
improvements using a chemical treatment. However, 
some concerns are yet to be addressed for widespread 
modeling of human diseases in vitro. In particular, each 
of the reports so far has reported a very limited number 
of established lines, and for disease modeling to be 
reliably explored, more control and patient lines need to 
be established in parallel using highly reproducible 
reprogramming methods. Another issue to consider is 
the delivery method of the reprogramming factors. Th  e 
most favorable are non-integrating methods that result in 
genetically unmodiﬁ  ed iPS cell lines. Th  is is especially 
important if the reprogrammed iPS cell lines will be 
utilized for clinical applications where reactivation of the 
reprogramming factors can result in unpredictable 
phenotypic outcomes, such as cancer development. A 
wide range of innovative techniques has resulted in 
successful reprogramming using pMX-based retroviral 
vectors, lentiviruses, non-integrating adenoviruses, 
episomal vectors, and plasmid and piggybac transposon 
systems. Although integration-free reprogramming 
methods are preferable, we have previously suggested 
that the use of retroviral transgenes provides a beacon of 
the completion of the reprogramming process and may 
be useful in cell lines not used for clinical applications 
[46]. Th   is feature has been exploited in numerous iPS cell 
studies investigating the dynamics of the reprogramming 
process [1,21]. Even with non-integrating reprogramming 
technologies, signiﬁ  cant heterogeneity between iPS cell 
lines may prove to be the biggest obstacle to reliable 
evaluation of disease phenotypes in vitro.
Th  e range of the normal phenotype of a particular 
functional assay is yet to be determined in multiple 
disease model settings. Only when the full range has been 
determined and reproducible diﬀ  erentiation  protocols 
have been established will we be able to model human 
diseases in culture with a high level of conﬁ  dence. Over-
coming this obstacle may involve determining the 
inherent variability in the starting population of undiﬀ  er-
entiated ESCs and iPS cells. It is unknown whether these 
variabilities will persist to the diﬀ  erentiated cell state. 
Although initial reports were highly encouraging as to 
the similarities between newly derived iPS cells and 
existing ESC lines, recent studies support thorough 
molecular characterization of clonal iPS cell lines, 
suggesting that signiﬁ  cant diﬀ  erences between iPS and 
ESCs remain at both the transcriptional [47] and 
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epigenetic marks in the undiﬀ   erentiated iPS cells will 
undoubtedly yield heterogenous diﬀ  erentiated cells for 
subsequent applications. In fact, a brief comparison of 
even human ESC lines demonstrated that diﬀ  erentiation 
preferences are highly inconsistent among human ESC 
lines, resulting in variable levels of lineage-speciﬁ  c gene 
activation [49]. Finally, pluripotent stem cells and adult 
mammalian progenitor cells have variable expression 
levels of genes controlling lineage speciﬁ  cation  [50]. 
Several genes with variable levels of expression in mouse 
ESCs have been described, with Nanog [51] and Stella 
[52], to our knowledge, being the best characterized. It 
remains to be investigated whether proper levels of 
variability of these pluripotency-related markers are 
established upon the transition of diﬀ  erentiated cells to 
fully reprogrammed iPS cells. In the case of Stella, 
variable gene expression is regulated by reversible 
epigenetic modiﬁ  cations such as histone acetylation in 
the ICM, with more long-term repressive epigenetic 
silencing through DNA methylation occurring at later 
stages of development, in the epiblast derived stem cells.
During these early phases of studying iPS cells, it is 
important to consider all possible obstacles to the safe 
and reliable use of iPS cells in these downstream 
applications [53]. Leading stem cell researchers remain 
cautious about possible false promises regarding the 
application of iPS cells. Th   e quality of the starting iPS cell 
lines for in vitro diﬀ   erentiation experiments may not 
need to be pluripotent to the strictest criteria, as long as 
the diﬀ  erentiation of the cell type of interest could be 
accomplished accurately and eﬃ   ciently. For this purpose, 
if one is interested in studying the cell types of the 
mesoderm lineage, the capacity of the iPS cell line to give 
rise to ectoderm/endoderm lineages may not be relevant. 
Even in these restricted directed diﬀ  erentiation experi-
ments, appropriate epigenetic circuitry needs to be 
established for the lineage-speciﬁ   c genes to be re-
expressed upon receiving diﬀ  erentiation signals.
Conclusions
Reprogramming of somatic cells progresses through 
several stages before the full pluripotent state is attained. 
We describe seven epigenetic features of reprogramming 
and illustrate their dynamic modiﬁ  cations at the diﬀ  erent 
stages. Small molecules can enhance eﬃ   ciencies  and 
further promote full reprogramming by modifying the 
epigenetic landscape. As we transition into large scale 
eﬀ  orts to make patient-speciﬁ  c iPS cell lines and model 
human diseases in vitro, proper epigenetic remodeling 
may remain at the forefront of stem cell biology, and 
developing methods to stably establish ESC-like 
epigenetic circuitry during the reprogramming process 
will be of high priority.
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